يعرض 61 - 80 نتائج من 145,495 نتيجة بحث عن '(((( 10 a decrease ) OR ( 50 ((ng decrease) OR (nn decrease)) ))) OR ( 50 we decrease ))', وقت الاستعلام: 2.28s تنقيح النتائج
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70
  11. 71

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis حسب Eric N. Ouattara (6890174)

    منشور في 2019
    "…In cost-effectiveness analysis, <i>Immediate ART</i> had a 10-year ICER of $680/YLS compared to <i>ART<350/μL</i>, ranging from cost-saving to an ICER of $1,440/YLS as transmission rates varied. …"
  12. 72
  13. 73

    S10 Data - حسب Christoph Anders (4068499)

    منشور في 2024
    "…The study was conducted with 25%, 50%, and 75% of the upper body weight. Additionally, we varied the starting point (forward tilt and backward tilt) and the direction of rotation. …"
  14. 74

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation حسب Kairui Yue (11874403)

    منشور في 2022
    "…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …"
  15. 75

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation حسب Kairui Yue (11874403)

    منشور في 2022
    "…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …"
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80